retatrutide regulatory status approval A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Weight Loss Blog – Maryland

That lower price tag comes with some big risks

As scientific understanding of sulforaphane deepens, it stands as a compelling candidate for targeted, mechanism-based interventions in autism spectrum disorder

As illustrated in Figure 1, this review comprehensively analyzes the mechanistic basis of GLP-1RAs in ocular diseases, synthesizes emerging clinical and preclinical evidence, and underscores their potential to redefine therapeutic strategies for vision-threatening disorders through multi-targeted disease modification

SoftwareX 12 , 1925 (2015)

Tirzepatide did not increase risks of adverse renal events, urinary tract infections, nephrolithiasis (kidney stones), acute kidney injury, or renal cancer compared to placebo, insulin, or other GLP-1 receptor agonists